News

María Rosa Durán , Ph.D., a member of the INiBICA’s MathMed group ( CO29: ) and a professor at the UCA, has won the 2025 Unstoppable Woman Award 👩‍🔬📊 The “Mujeres Imparables” Professional Network association held its 10th Anniversary Gala and the 2025 “Mujer Imparable Gaditana” Award this past Tuesday to a large and enthusiastic crowd. This year’s award went to María Rosa Durán, a colleague and scientist from Jerez who leads the “Recaída 0: Mathematics Against Childhood Leukemia” project. 🤝 This innovative event, which solidifies the “Mujeres Imparables” association’s position in the entrepreneurial landscape at both the regional and national levels, was attended by Government Delegate Mercedes Colombo Roque, Subdelegate Javier Ros Rodríguez, and Regional Delegates José Ángel Aparicio Hormigo and Carmen Sánchez Barrera. It was sponsored by the Provincial Council of Cádiz and supported by the City of Jerez. 💙 INiBICA celebrates this as a recognition of the talent, excellence, and dedication of a researcher who embodies the values of passion, commitment, perseverance, and inspiration to transform the province, using science to serve the well-being of society. 🏅 Congratulations to our colleague and to all the Mujeres Imparables. 🔗 More information: Diario de Jerez || Instagram

On November 20, 2025, at 9:30 a.m., we look forward to seeing you in the Auditorium of the School of Nursing and Physical Therapy (Avenida Ana de Viya, 52 – Cádiz) for the ConCIENCIA de Futuro Conference. 🎯 Objective: To familiarize early-career researchers (R1-R2) with the principles of the European Charter for Researchers and the Code of Conduct, as well as with the HRS4R process and its impact on professional development. 👉 Register by scanning the QR code or clicking the link below 🚀 Don’t miss this key event to boost your research career! 🔗 You can download the program at the link below 🔗 More information: Instagram

El pasado sábado 8 de noviembre, INiBICA participó en la 5ª Jornada de Promoción de la Salud “Más allá del diagnóstico: Nuevas Perspectivas”, organizada por la Asociación Conil Contra el Cáncer, un encuentro dedicado a compartir avances y fortalecer la colaboración entre pacientes, profesionales e investigadores. En representación de INiBICA, nuestra compañera Lourdes Rodríguez, Técnica de Gestión de Proyectos, asistió al acto de entrega de la donación que la Asociación realizó al Grupo EM18: Investigación, Desarrollo e Innovación en Medicina Materno-Fetal y en Oncología Ginecológica, liderado por el investigador Dr. Juan Jesús Fernández Alba, Jefe de Servicio de Obstetricia y Ginecología del Hospital Universitario Puerto Real, que desarrolla una destacada línea de investigación vinculada a la oncología ginecológica. Esta aportación representa un valioso impulso para la investigación biomédica, y un ejemplo inspirador del compromiso y la generosidad del movimiento asociativo de pacientes. Desde INiBICA queremos expresar nuestro agradecimiento más sincero por este gesto, que refuerza la unión entre ciencia, sociedad y salud.   🔗 Más información: Instagram

Our colleague Paula Castro Morales, a Projects , and Innovation Specialist, participated a few days ago in La Conectadora Azul (2nd edition), held as part of South Impact Cádiz 2025 🗣️ With more than 150 attendees and an average of three connections per person, the event generated over 450 conversations with real potential. 🤝 That is the true value of events like this: bringing together in one place research talent, companies, investors, and institutions with a common purpose—to take action. 💙 We thank UCA Emprende for the invitation and the organizing Team t for making it possible. 🔗 More information: Instagram

🗣️ On November 18, 2025, at 11:00 a.m., we will hold a training session to introduce two essential tools for new INiBICA staff: 📘 the Welcome Manual, which provides basic information on joining the institute, and the ✍️ OTM-R Hiring Policy, which explains how we ensure fair and transparent selection processes. FCÁDIZ Human Resources invites you to a scheduled Zoom meeting: 📘 Topic: Welcome Manual and OTM-R Hiring Policy 🕚 Time: November 18, 2025, 11:00 a.m. Amsterdam, Berlin, Rome, Stockholm, Vienna 💻 Join the Zoom meeting: HERE ▪️Meeting ID: 824 1940 6008 ▪️Access code: 2Xb3tw Please complete this QUESTIONNAIRE to assess your general prior knowledge of the topics to be covered in the upcoming seminar. 🔗 More information: Instagram

1️⃣ AWARD for the best startup in Andalusia: 🍏📲 GLUCOTYPP, whose team includes Dr. Felipe Monzo (College of Pharmacists, Board of Trustees of the INiBICA Management Foundation) and Dr. Alfonso Lechuga (Pediatrician at Puerta del Mar Hospital and Responsible researcher member of INiBICA’s CO1 Group and Professor at the UCA), whose mission is to personalize nutrition through the glucotype, combining science, technology, and artificial intelligence to improve people’s metabolic health. 2️⃣ AWARD for Best Pitch of the Conference, recognizing talent, innovation, and the ability to communicate Projects with real impact. 🌍✨ South Impact Cádiz 2025, an event that drives innovation with real impact on health and sustainability. CONGRATULATIONS, COLLEAGUES! 💙 🔗 More information: Instagram

¿Te apasiona la cardiología y la investigación clínica? Esta es tu oportunidad para seguir creciendo profesionalmente    Proyecto de cargo: FELLOW ELECTROFISIOLOGÍA HPM – Beca de formación en Electrofisiología Cardíaca Invasiva. Investigador Responsable: Lucas R. Cano Calabria. Titulación mínima requerida: Médicos/as especialistas en cardiología, tengan o no experiencia previa en la arritmología. Fecha de cierre: 10/11/2025.  ¡Inscríbete ahora y forma parte de nuestro equipo humano! En INiBICA no solo encontrarás un entorno de trabajo estimulante, sino también una oportunidad de disfrutar del entorno de la provincia de Cádiz Más información en este enlace Inscripción: AQUÍ

📅 Period: December 2025 – June 2026 🏥 Organized by: Hematology and Hemotherapy Department at the University Hospital of Jerez 🤝 In collaboration with: Cádiz Foundation, the Regional Government of Andalusia, GSK, Amgen, and AbbVie The Hematology and Hemotherapy Department at the Jerez University Hospital presents its new 2025–2026 Training Program, a series of scientific sessions designed to provide ongoing professional development for healthcare professionals in the fields of clinical hematology, applied research, and therapeutic innovation. Each session will include a 45-minute presentation, followed by the presentation of a research project or literature review developed by the department itself, promoting shared training and collaboration among specialists. 📘 Highlights of the program: Immune thrombotic purpura – December 4, 2025 Multiple myeloma: new criteria for response and progression – December 18, 2025 Lymphoma: update on treatment guidelines – January 15, 2026 Management of complications in allogeneic transplantation – January 29, 2026 Ph-negative CML and ALL: new treatment strategies – February 5, 2026 T-cell/NKT-cell lymphoma: update on the treatment of high-grade subtypes – February 19, 2026 Chronic lymphocytic leukemia – March 5, 2026 CAR-T Therapies: Advances and Updates – March 19, 2026 Myelodysplastic Syndromes – April 9, 2026 Hemostasis and Thrombosis – April 23, 2026 Acute Myeloblastic Leukemia – May 7, 2026 Infections in Hematology Patients – May 21, 2026 Paroxysmal Nocturnal Hemoglobinuria – June 11, 2026 Clinical Research and Collaborative Projects s of the Department – June 25, 2026 🗓️ Dates are tentative and may be adjusted according to the academic calendar and holidays. 🧬 General objective: To promote scientific updates and coordination among the various professionals in the field of hematology, fostering the creation of joint Projects and the continuous improvement of clinical practice. 📎 Organizational notes: Each session will include a theoretical-practical session with a literature review and open discussion. Sessions will be held at the Jerez University Hospital. The program will run throughout the 2025–2026 academic year. 📄 Download the complete program (PDF): HERE

📅 Date: Thursday, November 27, 2025 🕐 Time: 1:00 p.m. to 3:00 p.m. 📍 Location: Conference Room at Puerta del Mar Hospital (Ground Floor) The Institute for Biomedical Research and Innovation at Cádiz (INiBICA) is hosting the conference “Together for Health: Science, Patients, and Society—INiBICA’s Strategy for the Future,” an event designed to foster dialogue among researchers, patients, associations, companies, and the general public. During the session, the new INiBICA 2026–2030 Strategic Plan will be presented, addressing its main lines of action, challenges, and opportunities. In addition, there will be a participatory forum to discuss the role of clinical trials as a key tool for transforming healthcare through research, and to gather input from the various social stakeholders involved. 🔗 RSVP via this 👉 link 📄 Download the full program in PDF: HERE

🧬CAR therapies have made it possible to achieve cures for tumors that previously had no treatment options. However, limitations remain, such as toxicities, relapses mediated by antigenic escape, and challenges related to manufacturing, cost, and access. ⚙️To overcome these barriers, we present a modular system that separates a universal signaling module—responsible for activating the therapeutic cells—from one or more interchangeable recognition modules designed to identify tumors, allowing the specificity to be reoriented without having to reengineer the entire cell. 🧩The system allows for the targeted co-assembly of multiple targets with a single signaling scaffold, reducing the risk of antigenic escape by enabling the modification of recognition modules when changes occur in the tumors. The ability to modulate the presence of complete receptors by discontinuing the infusion of recognition modules will also allow for the control of toxicity and the depletion of therapeutic cells. 🌍The platform is also compatible with universal products, enabling the large-scale production of healthy donor cells with a common signaling module and the subsequent retrofitting of these cells with different recognition modules according to each patient’s needs. These universal CARs can be rapidly prepared for different tumor targets, with the ability to target multiple targets and fine-tune therapeutic activity to enhance the safety, efficacy, and accessibility of these therapies, enabling us to reach all patients in a timely manner. 🔬This innovation, which aims to improve safety (toxicity control), sustained efficacy (by mitigating antigenic escape and “fatigue” of therapeutic cells), and accessibility (standardized manufacturing of the signaling module and rapid “retrofitting” with recognition modules), is protected by a European patent pending, supplemented by Publications in two types of tumors—multiple myeloma and B-cell neoplasms—confirming the system’s versatility and its potential for patient-specific customization. 🔗 More information: Instagram